Expression of Interleukin-1 and Interleukin-1 Receptors Type 1 and Type 2 in Hodgkin Lymphoma by Oelmann, E. (Elisabeth) et al.
RESEARCH ARTICLE
Expression of Interleukin-1 and Interleukin-1
Receptors Type 1 and Type 2 in Hodgkin
Lymphoma
Elisabeth Oelmann1¤, Harald Stein2, Wolfgang E. Berdel1, Hermann Herbst3*
1 Department of Medicine A—Hematology/Oncology, University Hospital Muenster, Muenster, Germany,
2 Pathodiagnostik Berlin, Berlin, Germany, 3 Institute of Pathology, Vivantes Hospitals, Berlin, Germany
¤ Current address: Astra Zeneca, Cambridge, United Kingdom
* hermann.herbst@vivantes.de
Abstract
Signaling through the IL-1-receptor type 1 (IL-1R1), IL-1 is required for initiation and mainte-
nance of diverse activities of the immune system. A second receptor, IL-1R2, blocks IL-1
signal transduction. We studied expression of IL-1beta, IL-1R1, and IL-1R2 in 17 Hodgkin
lymphomas (HL) by in situ hybridization (ISH). IL-1beta expressing cells, morphologically
consistent with endothelial cells and fibroblasts, occurred in all HL tissues with elevated
transcript levels in areas of active fibrosis. Hodgkin and Reed-Sternberg (HRS) cells of all
cases expressed low IL-1R1 transcript levels in some tumor cells, and high levels of IL-1R2
in large proportions of HRS cells. Only few bystander cells showed low levels of IL-1R1 and
IL-1R2 RNA. Supernatants of 4 out of 7 HL-derived cell lines contained soluble IL-1R2 pro-
tein at high levels. HL patient sera carried variably amounts of IL-1R2 protein with signifi-
cantly increased titers in patients with active disease compared to patients in complete
remission and control individuals without HL. Western blots and co-immunoprecipitations
showed binding of the IL-1R2 to the intracellular IL-1R-accessory protein (IL-1IRAcP).
These data suggest functions of the IL-1R2 as a „decoy-receptor” sequestrating paracrine
IL-1 extracellularly and intracellularly by engaging IL-1IRAcP, thus depriving IL1-R1 mole-
cules of their extracellular and intracellular ligands. Expression of IL1-R2 by HRS cells
seems to contribute to local and systemic modulation of immune function in HL.
Introduction
Hodgkin lymphoma (HL) is characterized by a paucity of neoplastic Hodgkin- and Reed-Stern-
berg (HRS) cells, embedded in a variably composed reactive cellular infiltrate. HRS cells origi-
nate from B-cells [1]. Many of the distinct clinical and morphological features of HL, such as
B-symptoms and the cellular composition of the reactive infiltrate, are thought to be related to
a quantitatively and qualitatively abnormal expression of cytokines in HL lesions [2–5]. Some
cytokines have a potential to influence immune reactions and may be responsible for the escape
of HRS cells from T cell cytotoxicity [6]. This feature is particularly relevant in EBV-positive
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HL where HRS cells express viral neo-antigens known to be well controlled by T cells in healthy
virus carriers [7].
The majority of lymphocytes within HL lesions belongs to the CD4+ subpopulation and is
thought to have a Th2 cytokine production profile [4]. Notably in this context, HRS cells pro-
duce TGF-beta and IL-10, both of which may down modulate Th1 responses and are able to
induce apoptosis of activated FAS+/CD8+ T cells and NK cells via expression of Fas-ligand
(CD95L) [4]. Interleukin (IL-1)alpha and IL-1beta are pleiotropic cytokines with a broad spec-
trum of functions in various cell types and different tissues [8]. Both, IL-1alpha and IL-1beta
have significant amino acid homology, share biologic activities, and bind to the same cell sur-
face receptors, IL-1 receptors type 1 (IL-1R1) and type 2 (IL-1-R2) respectively [8]. Type 1
receptors mediate signaling [9] by interaction with the IL-1IRAcP, whereas type 2 receptors
may be released from cells and function as decoy receptors to block IL-1beta action [10]. In
addition, soluble IL-1 receptors (sIL-1R) and other naturally occurring antagonists for IL-1
such as IL-1 receptor antagonist (IL-1RA) have been described [11, 12]. Soluble IL-1R2 binds
to and blocks processing of IL-1beta precursor and loses affinity for IL-1 receptor antagonist
[13]. Thus, IL-1 activity seems to be the result of a finely tuned network of agonist and antago-
nist molecules within the IL-1 network.
IL-1, expressed by various haematopoetic and stromal cells, belongs to a group of cytokines
originally described as B-cell growth factors (BCGF) [14]. IL-1 is required for lymphocyte acti-
vation in general, and has distinct functions for lymphocyte subpopulations [14–23]. One of
the major co-stimulatory molecules in early T-cell activation [19–23], IL-1 prevents T-cell
anergy by stimulation of IL-2 and IL-2 receptors [23–26], especially in T-helper cells [23, 27,
28]. Along with IL-12 and IL-18, IL-1 supports differentiation of Th1 cells during T-helper cell
development [28]. Th2 cytokines downregulate IL-1 expression, whereas the antagonizing
molecule IL-1RA is up-regulated by Th2 cells [28, 29]. In concert with IL-2, IL-1 augments the
activating function of IL-2 on lymphokine activated killer cell (LAK)–activity [30–32], and
enhances the function of cytotoxic CD4 -, CD8—and NK cells in concert with IL-2 and inter-
ferons. IL-1 functions hereby as an enhancer of immunological defense mechanisms against
malignancies [33, 34]. Taken together IL-1 is involved in initiating and maintaining optimal
activated conditions of the immune system, preventing anergy and inducing elimination of
tumor cells. Regarding the direct effects of IL-1 on tumor cells, stimulation [35–37] as well as
inhibition [38–42] of growth has been observed with different tumor cells.
We studied IL-1 and its receptors in HL tissue sections, the presence of IL-1R2 in plasma of
HL patients, and the synthesis of these proteins by HL derived cell lines (HLDCL). Data suggest
a paracrine function of IL-1beta in HL lesions and a modulatory role of IL-1R2 as a specific
product of HRS cells likely to inhibit possible differentiating functions of IL-1 on the tumor cell
itself, and to induce anergy in the surrounding lymphoid tissue.
Patients and Methods
Patients
Lymph nodes were from 13 patients with nodular sclerosis (NSHL) and 10 patients with mixed
cellularity (MCHL) type of HL submitted for histopathological diagnosis prior to treatment.
Tissues were routinely formalin-fixed and paraffin-embedded. Slides from stored material
were grouped into NSHL or MCHL and otherwise completely anonymized. Heparin-plasma
from 20 patients treated in our department within the studies of the German Hodgkin Lym-
phoma Study Group were available to ELISA studies with HL in complete remission (CR) and
18 patients with active disease present (DP; NSHL or MCHL, no further selection). Plasma was
stored frozen. Aliquots were grouped for CR or DP, otherwise completely anonymized, and
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directly taken for ELISA analysis. Control plasma was from healthy individuals. Material was
destroyed after usage. This study was approved by the Ethical Board of the Faculty for Medi-
cine of the Westfaelische Wilhelms-Universitaet Muenster and the Physician´s Chamber of
Westfalen-Lippe (2015-174-f-S). Since old anonymized storage material was used, exemption
from written informed consent was granted.
HL derived cell lines
Hodgkin-Reed/Sternberg (H-R/S) cell derived cell lines (HLDCL) were kindly provided by
Prof. Volker Diehl (Univ. of Cologne, Germany), by Dr. D. B. Jones (Southampton, UK), and
Dr. H. Kamesaki (Kyoto, Japan). Morphology and immunophenotype of the cell lines have
been described [43]. Cell lines were cultured in AIMV-V medium (Gibco BRL, Gaithersburg,
MD, USA) without fetal calf serum (FCS). Cell lines repeatedly tested negative for mycoplasma
infection during the experiments.
In situ hybridization (ISH)
After linearisation of plasmids (pGEM-3Z, Promega, Madison, Wisconsin, USA) containing
specific sequences of the genes for hIL-1beta (R&D Systems, Minneapolis, USA) and hIL-1R
type 1 and type 2 (kindly provided by Immunex, Seattle, WA, USA), 35S-labeled run-off anti-
sense and sense (control-) transcripts were generated using Sp6 and T7 RNA polymerases
(Gibco BRL). ISH for the detection of RNA transcripts was performed as previously described
[2]. In brief, dewaxed and rehydrated paraffin sections were exposed to 0.2 N HCL and 0.125
mg/ml pronase (Boehringer, Mannheim, Germany) followed by acetylation with 0.1 M trietha-
nolamine pH 8.0/0.25% (v/v) acetic anhydride and dehydration through graded ethanols.
Slides were hybridized to 2–4 x 105 cpm of labeled probes overnight at 54°C. Washing and
autoradiography was performed as described [2]. All sections were processed in parallel using
the same batches of reagents and probes. The incubation of sections withMicrococcus nuclease
(Boehringer Mannheim, Mannheim, Germany) prior to in situ hybridization resulted in the
extinction of the specific autoradiographic signal, establishing that RNA sequences were the
targets of the hybridization procedure. ISH signals were semiquantitated by counting the pro-
portion of positive HRS cells and estimating the density of silver grains as the correlate for the
transcript levels.
Enzyme-linked immunosorbant assay (ELISA)
IL-1R2 plasma levels and levels in HLDCL supernatants were measured by ELISA kits (R+D
Systems, Wiesbaden, Germany) as described by the manufacturer. Plasma (stored at –80°C)
was measured either directly or after further dilution. Cells from cell lines were washed and cul-
tured at 106 cells per 20 ml of AIM-V medium for 48 hrs (pH 7.2, 37°C, 5% CO2 and high
humidity). Subsequently, culture supernatants were harvested, stored at –80°C and directly
taken for ELISA or assayed after further dilution.
Western blot, immunoprecipitation
Western blot and Immunoprecipitation were carried out according standard procedures. In
brief, cells from KMH2 (2 x 107 cells/300 microliter) were lysed with Special Lysis Buffer
(20mM Tris, pH 7.4, 1mM EGTA, 1mM EDTA, 2mMDTT, 0.5% TritonX-100) on ice, incu-
bated for 20 minutes at 4°C, centrifuged at 13000rpm at 4°C, and supernatants were stored at –
80°C. For Western blot 40 microliter of the lysate was boiled with 3 x SDS buffer for 5 minutes
and then transferred directly into a 4–15% ready to use gel (Bio-Rad Laboratories, München).
IL-1 and Receptors in Hodgkin Lymphoma
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For immunoprecipitation the lysates were first incubated with first antibodies and Sepharose-
G-beats over night and then centrifuged at 2500 rpm for 1 minute. The pellet was 3 x times
washed with Special Lysis Buffer, boiled with 3 x SDS, centrifuged at 2500 rpm for 1 minute,
and 20 microliter of the supernatant was transferred to the gel. The gel was running 1h 30 min-
utes and then transferred to a nitrocellulose membrane (Hybond ECL, Amersham Biosciences
Europe, Freiburg) for 3 h. The membrane was then blocked with 5% dry milk (Fluka Chemie,
Deisenhofen), incubated with the second antibody solution and washed with 1x PBS. Detection
was carried out with HRP conjugated antibodies and Luminol reagent (Santa Cruz Biotechnol-
ogy Inc., Heidelberg).
Statistics
Results were evaluated statistically by the Mann-Whitney test. P-values< .05 were interpreted
as indicating significant differences.
Results
IL-1beta RNA expression in HL tissue sections
IL-1beta expression was detected in all sections of 6 and 11 lymph nodes with MCHL and
NSHL, respectively (Fig 1A and 1B). The specific autoradiographic signal was most intense in
stromal cells of areas with active tissue remodeling and sclerosis (Fig 1B). Accordingly, there
was a significant difference between NSHL and MCHL with high transcript levels of IL-1beta
in NSHL (Fig 2). The expression pattern in MCHL was restricted to few stromal cells, morpho-
logically compatible with fibroblasts and endothelial cells, in scattered distribution throughout
the lesion (Fig 1A). In all HL cases, IL-1beta was absent from HRS cells at levels detectable by
our in situ hybridization technique.
Human IL-1 receptor type 1 and type 2 transcripts in HL tissue sections
Transcripts from both receptor genes were detectable in all of 17 HL cases (Fig 1C, 1D, 1E and
1F). HRS cells showed specific autoradiographic signals for both receptors, and particularly ele-
vated levels of IL-1R2 transcripts (Fig 1E). The signal intensity and the proportion of specifi-
cally labeled HRS cells varied between patients, with a range between 5% and 95% percent of
HRS cells per case within one tissue. IL-1R2 transcript levels in HRS cells were higher than IL-
1R1 transcript levels. The reactive lymphoid infiltrate showed irregularly distributed cells with
weak expression of the IL-1R1 (Fig 1D), whereas IL-1R2-positive reactive cells were particu-
larly rare (Fig 1E).
ELISA for IL-1R2 protein levels in supernatants from HLDCL
The cell lines, L591, L428, KMH2, and HDLM2 produced soluble IL-1R2 protein at concentra-
tions between 30 and 170 pg/ml in their supernatants (Fig 3A). Experiments were reproduced
twice with only little variation. Three of the cell lines, Sup-HD, Cole and L540 showed hIL-1R2
levels below the detection level and were thus considered non-producers.
ELISA for IL-1R2 protein in sera of HL patients and healthy controls
Sera from patients diagnosed with HL disease present (DP; n = 18), or in complete remission
(CR; n = 20) were studied for the presence of hIL-1R2 protein in comparison to normal indi-
viduals (CO; n = 10) (Fig 3B). Sera of all HL patients presented with variable levels of IL-1R2.
However, patients with active disease (progression of disease; DP) showed significantly higher
IL-1 and Receptors in Hodgkin Lymphoma
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levels compared to patients in complete remission (CR) and healthy individuals (controls; CR).
IL-1R2 serum levels of normal controls were similar to those of HL patients in CR.
Co-Immunoprecipitation of IL-1R2 and the IL-1 receptor accessory
protein IL-1IRAcP
Lysates from the IL-1R2 high producing cell line, KMH2, were studied to characterize a possi-
ble interaction of IL-1R2 with the IL-1IRAcP. Immunopreciptitation was carried out by
Fig 1. IL-1beta, IL-1R1, IL-1R2 expression in lymph node sections of patients with Hodgkin’s disease
as observed with in situHybridization (ISH) (Fig 1A–1F). Positive cells are characterized by accumulation
of black stains (examples illustrated with arrows).A) IL-1beta expression in few stromal and endothelial cells
throughout the lymph node of MC type HL. B) IL-1beta expression in the stromal cells of areas with tissue
remodeling and sclerosis in NSHL.C, D) IL-1R1 expression in HRS cells and few positive lymphocytes in
MCHL (C), and NSHL (D). E, F) IL-1R2 positive HRS cells in a case of MCHL (E) and NSHL (F).
doi:10.1371/journal.pone.0138747.g001
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incubating the KMH2-lysates with anti-IL-1IRAcP and subsequent characterization of the pre-
cipitate again with anti-IL-1IRAcP (Fig 4, left panel) to show that the immunoprecipitation
was successful. The Blot was then stripped and developed again with anti-IL-1R2 (Fig 4, right
panel). The bands observed, correspond to the established sizes of IL-1IRAcP and IL-1R2, of
66kDa and 68kDa respectively, verifying that IL-1IRAcP interact with IL-1R2 in KMH2. We
can not make any statement about the quantity of interacting receptors in vivo, because
depending on the effectiveness of the IP-reaction, anti-IL-1IRAcP is unlikely to absorb all of
the protein. This may explain why the supernatants display bands of both, IL-1IRAcP (Fig 4A,
SN) and IL-1R2 (Fig 4B, SN).
Discussion
Exploring the potential role of the IL-1 network in HL, we studied expression of IL-1beta,
IL-1R1, and IL-1R2. The results suggest a paracrine role for IL-1beta in HL and expression and
shedding of IL-1R2 as a mechanism by which HRS cells may modulate IL-1 activity intracellu-
larly and in their microenvironement.
Our finding of IL-1beta RNA expression in HL tissues confirms and extends previous
reports on IL-1alpha and IL-1beta expression. IL-1beta expressing cells were more numerous
in areas of active fibrosis in NSHL. IL-1beta has a fibrogenic effect, as shown by Postlethwaite
et al. [44] and this may contribute to the formal pathogenesis of NSHL, in particular. Unlike
Fig 2. IL-1beta expression in HRS cells as observed by ISH after 7, 14, and 21 days of
autoradiography.MCHL, mixed cellularity (n = 6). NSHL, nodular sclerosis (n = 11). Each circle represents 1
individual patient. Y-axis shows the relative expression level of positive cells, which comprises the number of
grains per cell and the expression intensity throughout the slide, with mean values and standard deviation.
There was a statistically significant difference between the histological subtypes after 21 days (p = .042,
Mann-Whitney test).
doi:10.1371/journal.pone.0138747.g002
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many other cytokines and growth factors, IL-1beta is not expressed by HRS cells at levels that
are detectable by our sensitive in situ hybridization technique. When activated by IL-1 convert-
ing enzyme, IL-1alpha and IL-1beta may bind to the IL-1R1 [8]. Signaling through this recep-
tor requires the presence of IL-1IRAcP to form an intracellular complex [9]. Expression of IL-
1R1 is typically found on normal B cells, hence the previous characterization of IL-1 as B-cell
growth factor, BCGF [14]. HRS cells were characterized as originating from B lymphocytes.
Therefore, IL-1R1 expression in some HRS cells may be reminiscent of that lineage.
Fig 3. IL-1R2 concentrations in supernatants and plasma. A) IL-1R2 concentration (pg/ml) in
supernatants of HL derived cell lines as measured by ELISA (for details see Materials and Methods). B) IL-
1R2 concentration in plasma of patients with Hodgkin’s disease (CR, complete remission; DP, active disease
present) in comparison to control persons (CO) as measured by ELISA (for details see Patients and
Methods). Each circle represents 1 individual person. Statistical comparison (Mann-Whitney test) revealed
significant differences when values were compared as follows: DP vs. CR (p = .037), DP vs. CO (p = .018),
CR vs. CO (p = .34).
doi:10.1371/journal.pone.0138747.g003
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Expression of IL-1R1, however, has to be viewed in the context of IL-1R2 expression, which,
according to our in situ hybridization patterns, was present in stronger signal intensities and in
larger proportions of tumor cells than expression of IL-1R1. IL-1R2 has functions as a ligand
sink through 3 mechanisms: membrane bound IL-1R2 interferes with IL-1 signaling by seques-
tration of the accessory protein, IL-1IRAcP, thus depriving the IL-1R1 from its intracellular
signaling partner [45–47], sIL-1R2 blocks processing of IL-1beta precursors [12], and the solu-
ble complex of IL-1R2 and IL-1IRAcP has an approximately 100-fold increased affinity for IL-
1 compared to sIL-1R2 alone [48]. Moreover, the latter complex does not bind IL-1RA, so that
these molecules are additionally available to antagonize IL-1R1. According to our data, it is
conceivable that all of these mechanisms may be functional in HL.
Most HRS cells in all of our cases expressed the IL-1R2 at significantly higher levels, and the
presence of sIL-1R2 in HLDCL supernatants and in HL patient sera suggest that the RNA is
translated to protein. Although we cannot exclude other sources of IL-1R2, we found high
amounts of IL-1R2 RNA almost exclusively in HRS cells, so that high IL-1R2 serum levels most
likely originate from these cells.
Counteracting the effects of IL-1 may be advantageous to HRS cells in their microenviron-
ment. In this context, its direct actions on tumor cells, either growth stimulatory [35–37, 49] or
Fig 4. A) Western blot (WB), immunoprecipitation (IP), and supernatants (SN) of the
immunoprecipitation reaction with anti-IL-1IRAcP is shown in the left panel (Fig 4A).Westernblot of
whole lysates of KMH2 is shown in the left lane (WB), the immunoprecipitated IL-1IRAcP is shown in the
middle lane (IP), and the supernatant of this IP-reaction (SN), is shown in the right lane. The blot was
detected also with the same antibody, anti-IL-1IRAcP, as a control reaction for the IP-reaction. The band in
the supernatant indicates, that there was too much protein to get all immunoprecipitated, so that the amount
of IL-1IRAcP, which was not bound by the antibody, occurs in the supernatant. IL-1IRAcP positive band is
shown at the expected size of 66kDa (black arrow). Y-axis, size markers. B) After stripping the blot, detection
was carried out with a specific anti-IL-1R2 antibody. Reactivity of the antibody was shown in theWB-, IP- and
SN-lanes of KMH2, showing that the cell line expresses high amounts of membrane bound IL-1R2 (WB),
which in part is able to interact with IL-1IRAcP (IP).
doi:10.1371/journal.pone.0138747.g004
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inhibitory [38–42], and the modulation of tumor specific cytotoxic CD4-, CD8- [30], LAK-
[31, 32] and NK-cells [50] are of interest and should be further studied.
The diversity of direct effects of IL-1 on tumor cells may be related to the differentiation sta-
tus of cells and also to the type of assay, most of which do not discriminate between prolifera-
tion as self renewal or as transition to the terminal stage of differentiation, as described for IL-1
function on glioblastomas [51]. In general, IL-1 functions involve signal transduction pathways
of GTP-binding proteins, such as sphingomyelinases, PKC, phospholipases, casein kinases,
and result in activation of MAP-kinase-, IκB/NFκB-, and c-Jun N-terminal kinase (JNK) fam-
ily members with subsequent transcription of genes such as by NFκB and AP-1 transcription
factors [52]. In B-cells, these Toll/IL-1 receptor pathways seem to be responsible for IL-1
effects, such as differentiation/proliferation and antibody synthesis [53–56], both of which may
be inhibited in HRS cells by sequestering IL-1IRAcP by IL-1R2.
In view of the extensive infiltration of HL lesions by cells of the immunosurveillance system,
immune escape mechanisms are of paramount importance to explain the existence of HRS
cells, in particular when expressing viral neo-antigens such as LMP1 in EBV-associated cases.
Previously, expression of IL-10, TIMP-1, TARC and other factors have been described with
immunomodulatory functions, and IL-1R2 expression seems to be an additional mechanism
counteracting immune activation. Expression of IL-1R2 seems to be one of the „road blocks”
[57] employed by HRS cells to interfere with normal immune functions of the surrounding
lymphocytes and to counteract IL-1 action on the tumor cells themselves.
Expression of IL-1R2 was originally found in Raji cells, an EBV-positive B-cell line [58, 59],
and IL-1R2 has sequence homology of approx. 30% to the Vaccinia virus gene B15R [60, 61].
Therefore, IL-1R2 expression may be regarded as a general mechanism of escape from IL-1
induced, adverse immune effects. In viral infections down modulation of IL-1 effects have two
aspects, protection of the virus-infected cell itself and protection of the host from excessive
inflammation [60]. Several lines of evidence indicate that the immunological function of IL-1
in Hodgkin’s disease is similarly inhibited, which may be partially explained by high amounts
of soluble IL-1R2.
Although IL-1 mediated effects were considered responsible for B-symptoms in progressive
Hodgkin’s disease, IL-1alpha and beta were, when detectable, present in only small amounts in
patients sera [62]. Presence of IL-1RA, as shown in some sera of Hodgkin patients [63], may
only partially contribute for this effect, because of its inability to bind the cytokine itself. Our
data show a significant correlation between sIL-1R2 expression by HRS-cells and the activity of
disease. The physiological function of sIL-1R2, to capture IL-1beta from the system, is therefore
enhanced in patients with progressive disease and could be the reason for only small amounts
of IL-1beta to be found in sera of Hodgkin’s patients. From the high levels of IL-1R2 RNA and
protein expression by HRS cells one can assume that the surrounding lymphoid tissue, neigh-
boring the tumor cells, is rendered unresponsive by inhibition of IL-1 dependent activation.
IL-1 is known as one main inducer of IL-2 responsiveness in T-cells, a function severely
impaired in HL: lymphocytes prepared from HD lesions have been shown to be defective in
producing IL-2 and IL-2 receptors with decreased proliferative response to PHA, with reduced
blastogenesis and T-cell colony formation [64–67]. Expression of IL-2 and IL-2 receptors in T-
cells from HL tissues is severely impaired [64, 66], moreover the proliferative response of nor-
mal PBMNCs is also severely inhibited, when cultivated with sera of Hodgkin’s patients [64].
Furthermore, blocking IL-1 function involves inhibition of IL-1 dependent signal transduction
pathways described above, probably also in the surrounding lymphocytes which would result
in inhibition of IL-1 dependent function in B-cells (differentiation/proliferation and antibody
synthesis) [53–56], in T-helper cells (differentiation towards Th1 cells) [28], in CD8+ T-cells
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(antigen-specific cross-priming) [68–70], and overall inhibition of stimulation of CD4/CD8
[17], NK [50, 69], gamma-delta T-cells [70] and LAK cells [31, 32].
In summary, we confirm earlier reports on expression of IL-1 in Hodgkin tissue [71–73]
and report for the first time on IL-1R2 transcripts and protein abundantly present in HRS cells,
which probably counteract IL-1 function systemically and in the microenvironment of the
Hodgkin lesion. IL-1R2 thereby may contribute to the spectrum of tumor induced immune
escape mechanisms by inhibition of IL-1, one of the earliest general T-cell co-stimulatory mole-
cules and by deprivation of HRS cells from regulation by IL-1. This observation may contribute
to understanding the complex signaling network within the Hodgkin lesion microenvironment
[73–75] and may help to explore new immune-therapy approaches for resistant cases [76].
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